GT Biopharma, Inc.
About GT Biopharma, Inc.
GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical stage immuno-oncology company focused on developing innovative therapies based on the Company's proprietary NK cell engager (TriKE®) technology. TriKE® therapeutic agents are targeted immunotherapeutic agents that simultaneously react with natural killer (NK) cells and cancer cells to selectively facilitate the killing of cancer cells. The company is generating novel immuno-oncology biopharmaceutical drugs targeting cancers such as acute lymphocytic leukemia and non-Hodgkin's lymphoma.
- 🔗 GT Biopharma, Inc. (GTBP)
- 🔗 GT Biopharma Reports First Quarter 2026 Financial Results :: GT Biopharma, Inc. (GTBP)
- 🔗 GT Biopharma - 2026 Company Profile, Team, Funding, Competitors & Financials - Tracxn
- 🔗 GT Biopharma, Inc. (GTBP) Business Profile — stockrow
- 🔗 GT Biopharma, Inc. (GTBP) Stock Price, News, Quote & History - Yahoo Finance
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- GT Biopharma holds approximately $9 million in cash as of March 31, 2026, expected to fund operations through Q4 2026.
- The company develops TriKE® NK cell engager therapies for cancers including acute lymphocytic leukemia and non-Hodgkin's lymphoma.
- GT Biopharma is a NASDAQ-listed public company (GTBP) with a history of nine funding rounds beginning in 2014.
- Headquartered in Brisbane, California, the firm focuses on targeted immunotherapies using proprietary platform technology.
Ask StreetZero about GT Biopharma, Inc.
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account